Norhan Mohammed, MD, PhD
Postdoctoral FellowAbout
Copy Link
Titles
Postdoctoral Fellow
Biography
Norhan Mohammed is an MD-PhD–trained translational researcher with a focus on gastroenterology and hepatology. She earned her medical degree at Assiut University in Egypt, followed by clinical training in Gastroenterology and Hepatology at Assiut University Hospital before transitioning to full-time research. Norhan completed a Master’s in Medical Biochemistry with a concentration on the genetics of Gaucher disease, and subsequently received her PhD in Biochemistry (Summa Cum Laude) from Florida International University. Her doctoral work in cancer glycobiology resulted in three first-authored publications, several co-authorships, multiple conference presentations, and a pending U.S. patent.
Norhan continued her cancer research as a Postdoctoral Fellow at NYU Grossman School of Medicine through a competitive NIH T32 training grant. She later received an additional NIH T32 award in Investigative Gastroenterology, supporting her transition into GI-focused research as a Postdoctoral Fellow at Yale University, where she investigates the genetic drivers of portal hypertension. Norhan is pursuing a career as a physician-scientist in gastroenterology with an emphasis on precision medicine and improving patient outcomes.
Departments & Organizations
Education & Training
- Postdoctoral Associate
- Yale University
- Postdoctoral Fellow
- New York University
- PhD
- Florida International University
- MD
- Assiut University
Research
Copy Link
Publications
Featured Publications
Melanoma Glycome Regulates the Pro-Oncogenic Properties of Extracellular Galectin-3.
Mohammed NBB, Shil RK, Dimitroff CJ. Melanoma Glycome Regulates the Pro-Oncogenic Properties of Extracellular Galectin-3. Int J Mol Sci 2025, 26 PMID: 40430022, DOI: 10.3390/ijms26104882.Peer-Reviewed Original ResearchTumor-Intrinsic Galectin-3 Suppresses Melanoma Metastasis.
Mohammed NBB, Lau LS, Souchak J, Qiu S, Ahluwalia MS, Osman I, Dimitroff CJ. Tumor-Intrinsic Galectin-3 Suppresses Melanoma Metastasis. J Invest Dermatol 2024, 144: 2039-2051.e9. PMID: 38458429, DOI: 10.1016/j.jid.2024.02.011.Peer-Reviewed Original ResearchThe pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma.
Mohammed NBB, Antonopoulos A, Dell A, Haslam SM, Dimitroff CJ. The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma. Adv Cancer Res 2023, 157: 157-193. PMID: 36725108, DOI: 10.1016/bs.acr.2022.06.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2025
Investigating the potential scabicidal activities of three essential oils: gaining mechanistic insights through in vitro contact bioassay and molecular docking.
Wahman R, Mohamed S, Bayoumi S, Morsy R, Shafie S, Abdelraheem N, Abdelaziz F, Hussein S, Ibrahim R, Mohammed N, Yones D, Mohammed S, Ahmad A. Investigating the potential scabicidal activities of three essential oils: gaining mechanistic insights through in vitro contact bioassay and molecular docking. BMC Complement Med Ther 2025, 25: 185. PMID: 40405160, DOI: 10.1186/s12906-025-04868-0.Peer-Reviewed Original Research
2024
Galectin-9 - ligand axis: an emerging therapeutic target for multiple myeloma.
Shil RK, Mohammed NBB, Dimitroff CJ. Galectin-9 - ligand axis: an emerging therapeutic target for multiple myeloma. Front Immunol 2024, 15: 1469794. PMID: 39386209, DOI: 10.3389/fimmu.2024.1469794.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThe role of galectins in mediating the adhesion of circulating cells to vascular endothelium.
Souchak J, Mohammed NBB, Lau LS, Dimitroff CJ. The role of galectins in mediating the adhesion of circulating cells to vascular endothelium. Front Immunol 2024, 15: 1395714. PMID: 38840921, DOI: 10.3389/fimmu.2024.1395714.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2023
Hypoxia Controls the Glycome Signature and Galectin-8-Ligand Axis to Promote Protumorigenic Properties of Metastatic Melanoma.
Chakraborty A, Perez M, Carroll JD, Antonopoulos A, Dell A, Ortega L, Mohammed NBB, Wells M, Staudinger C, Griswold A, Chandler KB, Marrero C, Jimenez R, Tani Y, Wilmott JS, Thompson JF, Wang W, Sackstein R, Scolyer RA, Murphy GF, Haslam SM, Dimitroff CJ. Hypoxia Controls the Glycome Signature and Galectin-8-Ligand Axis to Promote Protumorigenic Properties of Metastatic Melanoma. J Invest Dermatol 2023, 143: 456-469.e8. PMID: 36174713, DOI: 10.1016/j.jid.2022.07.033.Peer-Reviewed Original Research
2022
Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy.
Lau LS, Mohammed NBB, Dimitroff CJ. Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy. Int J Mol Sci 2022, 23 PMID: 36555198, DOI: 10.3390/ijms232415554.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsEvaluation of the Revised Trauma Score, MGAP, and GAP scoring systems in predicting mortality of adult trauma patients in a low-resource setting.
Mohammed Z, Saleh Y, AbdelSalam EM, Mohammed NBB, El-Bana E, Hirshon JM. Evaluation of the Revised Trauma Score, MGAP, and GAP scoring systems in predicting mortality of adult trauma patients in a low-resource setting. BMC Emerg Med 2022, 22: 90. PMID: 35643425, DOI: 10.1186/s12873-022-00653-1.Peer-Reviewed Original ResearchAnalysis of Galectin-Binding Receptors on B Cells.
Chakraborty A, Mohammed NBB, Bernasconi AE, Dimitroff CJ. Analysis of Galectin-Binding Receptors on B Cells. Methods Mol Biol 2022, 2442: 565-580. PMID: 35320546, DOI: 10.1007/978-1-0716-2055-7_30.Chapters
News
Copy Link
Get In Touch
Copy Link